Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Policy / Regulatory

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Fineline Cube Jul 29, 2026
Company Drug

Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients

Fineline Cube Jul 29, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership

Fineline Cube Jul 29, 2026
Company Drug

Antengene’s ATG-008 Shows Promising Results in Cervical Cancer and Hepatocellular Carcinoma Studies

Fineline Cube Nov 16, 2022

Shanghai-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced positive preliminary results from the TORCH-2...

Company Drug

CStone Pharmaceuticals Launches AML Public Welfare Project with China Social Welfare Foundation

Fineline Cube Nov 16, 2022

The acute myeloid leukemia (AML) public welfare project, initiated by the China Social Welfare Foundation...

Company Drug

Betta Pharmaceuticals’ BPI-D0316 Accepted for NMPA Review for NSCLC Adjuvant Therapy

Fineline Cube Nov 16, 2022

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that its clinical trial filing for...

Company Drug

Kelun-Biotech’s SKB264 Receives FDA Approval for Phase II Study

Fineline Cube Nov 16, 2022

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the US FDA to...

Company Deals

Junovabio Secures Pre-Series A Funding for Tumor Molecular Diagnosis

Fineline Cube Nov 16, 2022

Junovabio, a Shanghai-based molecular diagnostics specialist, has reportedly raised “tens of millions” of renminbi in...

Company Deals

Lupeng Pharma Raises USD 35 Million in Pre-Series B Financing Round

Fineline Cube Nov 16, 2022

China-based Lupeng Pharmaceutical Ltd has reportedly raised USD 35 million in Phase 2 of a...

Company Drug

Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa

Fineline Cube Nov 15, 2022

Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE:...

Company Deals

Silk Round Fund and INA Invest in Indonesian Pharma Companies

Fineline Cube Nov 15, 2022

The Chinese state-owned Silk Round Fund (SRF) and Indonesia’s sovereign fund INA have reportedly agreed...

Company Drug

LaNova Medicines Gets NMPA Approval for LM-305 Clinical Study

Fineline Cube Nov 15, 2022

Shanghai-based cancer therapy developer LaNova Medicines Ltd has announced that it has received approval from...

Company Drug

Everest Medicines’ Nefecon NDA Accepted for IgA Nephropathy in China

Fineline Cube Nov 15, 2022

China-based biotech Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has...

Company

CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs

Fineline Cube Nov 15, 2022

CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of...

Company Medical Device

Hotgen Receives NMPA Approval for HBV RNA Assay Kit

Fineline Cube Nov 15, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced that it has received marketing approval...

Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity

Fineline Cube Nov 15, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first patient dosing in the randomized,...

Company Drug

Guangdong Zhongsheng Starts Phase III Trial for COVID-19 Drug RAY1216

Fineline Cube Nov 15, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the enrollment of the first...

Company Drug

Yabao Receives FDA Clearance for Generic Nexavar

Fineline Cube Nov 15, 2022

China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received Abbreviated...

Company Deals

Hansoh Pharmaceutical Licenses Biotheus’ Bispecific Antibody PM1080 for Greater China

Fineline Cube Nov 15, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with fellow...

Company Deals

Sansure Biotech Partners with UBC to Manufacture in Indonesia

Fineline Cube Nov 15, 2022

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has entered into a local manufacturing...

Company

HutchMed Shifts Focus to Late-Stage Pipeline for Regulatory Approvals

Fineline Cube Nov 15, 2022

Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced a strategic shift to focus...

Company Deals

Harbour BioMed and WuXi Biologics Announce Strategic Collaboration

Fineline Cube Nov 15, 2022

Harbour BioMed (HKG: 2142), a global biotechnology company with operations in the United States, the...

Company Drug

Hengrui’s Pyrotinib Granted Priority Review for HER2-Positive Breast Cancer

Fineline Cube Nov 15, 2022

The Center for Drug Evaluation (CDE) website has announced that China-based Hengrui Pharmaceuticals’ (SHA: 600276)...

Posts pagination

1 … 635 636 637 … 701

Recent updates

  • GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations
  • Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
  • Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership
  • Shionogi Launches XOCOVA (Ensitrelvir) in US for COVID-19 Post-Exposure Prophylaxis Following 67% Risk Reduction in Global Trial
  • Insilico Medicine’s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations

Company Drug

Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership

Company Drug

Shionogi Launches XOCOVA (Ensitrelvir) in US for COVID-19 Post-Exposure Prophylaxis Following 67% Risk Reduction in Global Trial

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.